Ontology highlight
ABSTRACT: Purpose
Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) -targeted drugs in patients with non-small-cell lung cancer (NSCLC). We investigated whether dual inhibition of MET/EGFR results in clinical benefit in patients with NSCLC.Patients and methods
Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib; crossover was allowed at progression. Tumor tissue was required to assess MET status by immunohistochemistry (IHC). Coprimary end points were progression-free survival (PFS) in the intent-to-treat (ITT) and MET-positive (MET IHC diagnostic positive) populations; additional end points included overall survival (OS), objective response rate, and safety.Results
There was no improvement in PFS or OS in the ITT population (n = 137; PFS hazard ratio [HR], 1.09; P = .69; OS HR, 0.80; P = .34). MET-positive patients (n = 66) treated with erlotinib plus onartuzumab showed improvement in both PFS (HR, .53; P = .04) and OS (HR, .37; P = .002). Conversely, clinical outcomes were worse in MET-negative patients treated with onartuzumab plus erlotinib (n = 62; PFS HR, 1.82; P = .05; OS HR, 1.78; P = .16). MET-positive control patients had worse outcomes versus MET-negative control patients (n = 62; PFS HR, 1.71; P = .06; OS HR, 2.61; P = .004). Incidence of peripheral edema was increased in onartuzumab-treated patients.Conclusion
Onartuzumab plus erlotinib was associated with improved PFS and OS in the MET-positive population. These results combined with the worse outcomes observed in MET-negative patients treated with onartuzumab highlight the importance of diagnostic testing in drug development.
SUBMITTER: Spigel DR
PROVIDER: S-EPMC4878106 | biostudies-literature | 2013 Nov
REPOSITORIES: biostudies-literature
Spigel David R DR Ervin Thomas J TJ Ramlau Rodryg A RA Daniel Davey B DB Goldschmidt Jerome H JH Blumenschein George R GR Krzakowski Maciej J MJ Robinet Gilles G Godbert Benoit B Barlesi Fabrice F Govindan Ramaswamy R Patel Taral T Orlov Sergey V SV Wertheim Michael S MS Yu Wei W Zha Jiping J Yauch Robert L RL Patel Premal H PH Phan See-Chun SC Peterson Amy C AC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20131007 32
<h4>Purpose</h4>Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) -targeted drugs in patients with non-small-cell lung cancer (NSCLC). We investigated whether dual inhibition of MET/EGFR results in clinical benefit in patients with NSCLC.<h4>Patients and methods</h4>Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus e ...[more]